PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Investor Presentation (April 2019)

32 slides from PhaseBio Pharmaceuticals's investor presentation, Apr 10, 2019

  1. Slide 1: Corporate Overview April 2019

    Corporate Overview April 2019 Exhibit 99.1

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”)

  3. Slide 3: Company Overview

    Company Overview Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications Product Candidates PB2452 – Novel agent for immediate and sustained reversal of ticag

  4. Slide 4: A Clinical Stage, Orphan Disease-Focused Biopharmaceutical Company

    Program Indication/Therapeutic Area Pre-Clinical Phase 1 Phase 2 Phase 3 WW Commercial Rights Milestones PB2452 Reversal of Ticagrelor Antiplatelet Activity 1H 2019: Initiate Phase 2a Report Phase 2a results 2H 2019: Initiate Phase 2b 2020: Initiate Phase 3 based on plan to pursue accelerated regula

  5. Slide 5: Corporate

    Corporate

  6. Slide 6: Recent Corporate Highlights

    Recent Corporate Highlights PB2452 granted Breakthrough Therapy designation by FDA in April 2019 Breakthrough Therapy designation is designed to expedite the development and review of promising new drugs Reported PB2452 Phase 1 results Presented as a late breaking oral presentation at the American C

  7. Slide 7: Full-Year 2018 Financial Highlights

    Full-Year 2018 Financial Highlights Operating expense: $20.3M R&D: $15.5M SG&A: $4.9M Loss from Operations: ($19.6M) Net Loss of ($23.8M) or ($4.49) per share 5.3M shares used for computing FY 2018 net loss per share Cash and cash equivalents as of 12/31/2018: $61.0M Shares outstanding as of 03/15/2

  8. Slide 8: Experienced Management Team

    Experienced Management Team JONATHAN MOW Chief Executive Officer Amylin Pharmaceuticals, Corus Pharma, PathoGenesis, BMS JOHN SHARP Chief Financial Officer Ligand Pharmaceuticals, HUYA Bioscience, Sequenom, Diversa JOHN LEE, MD, PhD, FACC Chief Medical Officer Merck, BMS, Quintiles SUSAN ARNOLD, PhD

  9. Slide 9: PB2452 – Reversal Agent for Ticagrelor

    PB2452 – Reversal Agent for Ticagrelor

  10. Slide 10: PB2452 - Novel reversal agent for Brilinta (ticagrelor)

    PB2452 - Novel reversal agent for Brilinta (ticagrelor) Human monoclonal antibody fragment (Fab), delivered intravenously in the hospital Phase 1 Proof of Concept Study completed Selected for late-breaking oral presentation American College of Cardiology’s Annual Scientific Session (March 17, 2019)

  11. Slide 11: PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor

    PB2452: Well-Characterized Mechanism of Reversal of Ticagrelor ADP ADP Platelet ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation This is a reversible process with ticagrelor cycling on/off the P2Y12 receptors PB2452:ticag

  12. Slide 12: PB2452 Granted Breakthrough Therapy Designation

    PB2452 Granted Breakthrough Therapy Designation In April 2019, PB2452 was granted Breakthrough Therapy designation by FDA Designation supported by Phase 1 trial results, which were recently published in the New England Journal of Medicine1 Breakthrough Designation may be granted by FDA when prelimin

  13. Slide 13: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects

    PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects Selected as late-breaking oral presentation during featured clinical research session at the American College of Cardiology’s Annual Scientific Session – March 17, 20191 Simultaneously published in the New England Journal of Medicine2 https:/

  14. Slide 14: PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects

    PB2452 Phase 1 Proof-of-Concept Study in Healthy Subjects Randomized, double-blind, placebo-controlled, single ascending dose (SAD), sequential group study (n=64) 3:1 randomization, PB2452-Placebo Higher-dose cohorts pre-treated with ticagrelor After 48 hours of ticagrelor, platelet aggregation was

  15. Slide 15: PB2452 Phase 1 Trial Design

    PB2452 Phase 1 Trial Design Cohort Ticagrelor Pretreatment PB2452 IV regimen Volunteers Active:Placebo 1 None 0.1g 30 min 3A:1P 2 None 0.3g 30 min 3A:1P 3 None 1g 30 min 3A:1P 4 180mg PO + 90mg BID x 2 days 1g 30 min 6A:2P 5 180mg PO + 90mg BID x 2 days 3g 30 min 6A:2P 6 180mg PO + 90mg BID x 2 days

  16. Slide 16: Platelet Function After Ticagrelor Reversal - LTA

    Nominal Time (h) Platelet Function After Ticagrelor Reversal - LTA Normalization of platelet response to ADP was assessed by whether reversal of ticagrelor achieved a normal range of platelet function Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-Based Ticagrelor Reversal Agent in Healthy Voluntee

  17. Slide 17: Platelet Aggregation with AA and TRAP

    %Platelet aggregation by AA Nominal Time (h) Platelet Aggregation with AA and TRAP Mean platelet aggregation by LTA using AA (top) or TRAP (bottom) as agonist %Platelet aggregation by TRAP Nominal Time (h) Arachidonic acid (AA) Thrombin receptor activating peptide (TRAP) No platelet rebound effect o

  18. Slide 18: Treatment-Emergent Adverse Events

    Treatment-Emergent Adverse Events Preferred Term All Placebo (N=16) n (%) All PB2452 (N=48) n (%) Total Number of TEAEs 3 27 Number of volunteers with at Least 1 TEAE 2 (12.5) 17 (35.4) Infusion site bruising 0 4 (8.3) Medical device site reaction 0 3 (6.3) Infusion site extravasation 0 2 (4.2) Vess

  19. Slide 19: PB2452 Clinical Development Plan Based on FDA Accelerated Approval Pathway

    PB2452 Clinical Development Plan Based on FDA Accelerated Approval Pathway Regulatory Strategy Based on Pre-IND Discussion of Accelerated Approval Phase 2a trial to confirm dosing in an older, healthy-for-age population Large Phase 2b trial will develop BLA safety database Phase 3 non-randomized tri

  20. Slide 20: Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 approval

    Continued Long Term Unit Growth of Ticagrelor Fueled by PB2452 approval Brilinta/Brilique sales in 2018 were $1.32B and growing (+22% Y/Y) Patient growth drives Y/Y revenue growth in all regions: EU (+18%), US (+16%), Emerging Markets (+46%) In February 2019, Brilinta Phase III THEMIS1 trial met pri

  21. Slide 21: PB2452 Program Summary and Next Steps

    PB2452 Program Summary and Next Steps Phase 1 trial achieved clinically-important immediate and sustained reversal of ticagrelor Well tolerated and no PB2452-related SAEs Product profile: Immediate and sustained reversal of ticagrelor antiplatelet effects Major bleeding requires immediate and sustai

  22. Slide 22: Elastin-Like Polypeptide Technology (ELP) – Engine for Growth

    Elastin-Like Polypeptide Technology (ELP) – Engine for Growth

  23. Slide 23: Prolonged Circulating Half-Life with ELP Technology

    PROLONGED CIRCULATING HALF-LIFE Repeating Sequence of Human Elastin Peptides VPGXG Peptide/Protein (VIP, GLP1, etc.) Active Moiety “Biopolymer” n UP TO 200x INCREASE IN ½ LIFE Proprietary Elastin-Like Polypeptide (ELP) Technology Growth Engine for PhaseBio Preclinical Pipeline ↑ Temperature COACERVA

  24. Slide 24: ELP: A Highly Flexible Technology for Modulating Pharmacokinetics

    ELP: A Highly Flexible Technology for Modulating Pharmacokinetics VERSATILE: MANY ACTIVE MOIETIES POSSIBLE Peptides or proteins can be genetically fused to N- or C-terminus1, or both. Chemical conjugation to small molecules or peptides LOW COST MANUFACTURING Can be produced in E.coli, yeast or mamma

  25. Slide 25: PB1046 - Once Weekly VIP Analog for Pulmonary Arterial Hypertension

    PB1046 - Once Weekly Vasoactive Intestinal Peptide (VIP) Analog for Pulmonary Arterial Hypertension

  26. Slide 26: High Unmet Need in an Orphan Disease

    High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) High unmet need for novel disease-modifying PAH therapies for greater efficacy All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways Patients inevitab

  27. Slide 27: PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug

    PB1046: Harnessing VIP to Create a Stable, Long-Acting Drug PRECLINICAL STUDIES Support Clinical Development for: Pulmonary Arterial Hypertension DMD Cardiomyopathy Heart Failure (Chemotherapy-Induced HF or HFpEF) Cystic Fibrosis MECHANISM OF ACTION VIA VPAC2 RECEPTOR Potent vasodilator Anti-inflamm

  28. Slide 28: PB1046 Phase 1 and 2a Studies Completed

    PHASE 1 Studies Completed PAH PHASE 2 Studies Well tolerated for a week over broad range of exposure; no drug-related SAEs Prolonged PK/PD profile over 1 week VIP activity confirmed (Systolic and Diastolic BP lowering) Well tolerated across dose range; no drug-related SAEs Replicated PK/PD from SAD

  29. Slide 29: PB1046 Single Ascending Dose Study

    PB1046 Single Ascending Dose Study PK and PD Support Once-Weekly SC Administration Single subcutaneous injections in hypertensive patients washed off medications Well tolerated, week-long PK, dose-dependent VIP activity observed Supports weekly SC dosing in multi-dose studies Serum Concentration PB1

  30. Slide 30: PB1046 Multiple Ascending Dose Study

    PB1046 Multiple Ascending Dose Study Multi-Dose Safety and PK/PD Confirmed in HFrEF Patients MAD in HFrEF completed 4Q2017 Weekly SC injections x 4 weeks in 29 HF patients maintained on SOC meds Well tolerated in a sick patient population on multiple vasoactive medications Prolonged PK profile repli

  31. Slide 31: PB1046 Phase 2b PAH Study Actively Recruiting

    PB1046 Phase 2b PAH Study Actively Recruiting PAH WHO functional class II/III subjects on two drug oral SOC therapy 16 week randomized, double-blinded, controlled study with extension Primary endpoints: Pulmonary vascular resistance (PVR) via RHC, 6MWD, safety Designed to support placebo-controlled

  32. Slide 32: Slide 32

PhaseBio Pharmaceuticals — Investor Presentation (April 2019) on 6ix